Mutual of America Capital Management LLC Sells 67,108 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Key Points

• Mutual of America Capital Management LLC reduced its holdings in Halozyme Therapeutics by 37.8%, selling 67,108 shares and retaining 110,242 shares worth approximately $7 million.
• Several institutional investors, including Bessemer Group Inc. and UMB Bank n.a., have significantly increased their stakes in Halozyme Therapeutics during the first quarter of this year.
• Halozyme Therapeutics has received mixed ratings from analysts, with price targets ranging from $55.00 to $75.00, reflecting several upgrades and downgrades affecting the stock's consensus rating.

Mutual of America Capital Management LLC decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 37.8% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 110,242 shares of the biopharmaceutical company's stock after selling 67,108 shares during the period. Mutual of America Capital Management LLC owned about 0.09% of Halozyme Therapeutics worth $7,035,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of HALO. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics during the fourth quarter valued at about $29,000. Bessemer Group Inc. lifted its position in shares of Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares during the last quarter. Park Place Capital Corp boosted its holdings in shares of Halozyme Therapeutics by 20.1% in the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after buying an additional 182 shares in the last quarter. UMB Bank n.a. grew its position in shares of Halozyme Therapeutics by 267.4% in the 1st quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company's stock worth $84,000 after buying an additional 960 shares during the last quarter. Finally, Parallel Advisors LLC raised its stake in shares of Halozyme Therapeutics by 12.5% during the 1st quarter. Parallel Advisors LLC now owns 1,875 shares of the biopharmaceutical company's stock worth $120,000 after acquiring an additional 208 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Analysts Set New Price Targets

HALO has been the subject of several recent analyst reports. HC Wainwright raised their target price on shares of Halozyme Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday. Wells Fargo & Company raised their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Leerink Partnrs lowered Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. The Goldman Sachs Group initiated coverage on Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price target for the company. Finally, Morgan Stanley upgraded Halozyme Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $62.00 to $75.00 in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of "Hold" and an average price target of $66.56.

Halozyme Therapeutics Stock Down 0.4%

Shares of HALO stock opened at $62.10 on Friday. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $70.50. The firm has a market capitalization of $7.65 billion, a PE ratio of 14.21, a P/E/G ratio of 0.42 and a beta of 1.17. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.30 and a current ratio of 8.36. The stock's 50-day simple moving average is $55.84 and its 200-day simple moving average is $57.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. During the same quarter in the prior year, the company earned $0.91 EPS. Halozyme Therapeutics's quarterly revenue was up 40.8% on a year-over-year basis. Equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $56.43, for a total transaction of $1,128,600.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at $41,403,763.17. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 60,000 shares of company stock valued at $3,262,400 in the last quarter. 2.40% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.